doi:10.3969/j.issn.1004-583X.2024.12.012

Abstract

CLC Number:

Add to citation manager EndNote|Ris|BibTeX

URL: https://lchc.magtechjournal.com/EN/10.3969/j.issn.1004-583X.2024.12.012

https://lchc.magtechjournal.com/EN/Y2024/V39/I12/1125

References 55

[1]	Xue C, Yao Q, Gu X, et al. Evolving cognition of the JAK-STAT signaling pathway: Autoimmune disorders and cancer[J]. Signal Transduct Target Ther, 2023, 8(1):204.
[2]	Roskoski RJ. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders[J]. Pharmacol Res, 2022, 183:106362.
[3]	Hu Q, Bian Q, Rong D, et al. JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens[J]. Front Bioeng Biotechnol, 2023, 11:1110765.
[4]	Núñez P, Quera R, Yarur AJ. Safety of Janus kinase inhibitors in inflammatory bowel diseases[J]. Drugs, 2023, 83(4):299-314. doi: 10.1007/s40265-023-01840-5 pmid: 36913180
[5]	Assal A, Mapara MY. Janus kinase inhibitors and cell therapy[J]. Front Immunol, 2021, 12:740847.
[6]	Henry SP, Jorgensen WL. Progress on the pharmacological targeting of Janus pseudokinases[J]. J Med Chem, 2023, 66(16):10959-10990. doi: 10.1021/acs.jmedchem.3c00926 pmid: 37578217
[7]	Yang X, Yan H, Jiang N, et al. IL-6 trans-signaling drives a STAT3-dependent pathway that leads to structural alterations of the peritoneal membrane[J]. Am J Physiol Renal Physiol, 2020, 318(2):F338-F353.
[8]	Hu X, Li J, Fu M, et al. The JAK/STAT signaling pathway: From bench to clinic[J]. Signal Transduct Target Ther, 2021, 6(1):402.
[9]	Chen H, Bian A, Zhou W, et al. Discovery of the highly selective and potent STAT3 inhibitor for pancreatic cancer treatment[J]. ACS Cent Sci, 2024, 10(3):579-594.
[10]	Li YJ, Zhang C, Martincuks A, et al. STAT proteins in cancer: Orchestration of metabolism[J]. Nat Rev Cancer, 2023, 23(3):115-134.
[11]	Du W, Liu N, Zhang Y, et al. PLOD2 promotes aerobic glycolysis and cell progression in colorectal cancer by upregulating HK2[J]. Biochem Cell Biol, 2020, 98(3):386-395. doi: 10.1139/bcb-2019-0256 pmid: 31742425
[12]	Guo X, Jiang C, Chen Z, et al. Regulation of the JAK/STAT signaling pathway in spinal cord injury: An updated review[J]. Front Immunol, 2023, 14:1276445.
[13]	Liang D, Wang Q, Zhang W, et al. JAK/STAT in leukemia: A clinical update[J]. Mol Cancer, 2024, 23(1):25. doi: 10.1186/s12943-023-01929-1 pmid: 38273387
[14]	Goetsch A, D'Amico F, Allocca M, et al. Advances in pharmacotherapy for ulcerative colitis: A focus on JAK1 inhibitors[J]. Expert Opin Pharmacother, 2023, 24(7):849-861. doi: 10.1080/14656566.2023.2200931 pmid: 37038911
[15]	Luo Y, Alexander M, Gadina M, et al. JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition[J]. J Allergy Clin Immunol, 2021, 148(4):911-925. doi: 10.1016/j.jaci.2021.08.004 pmid: 34625141
[16]	Muller R. JAK inhibitors in 2019, synthetic review in 10 points[J]. Eur J Intern Med, 2019, 66:9-17. doi: S0953-6205(19)30182-7 pmid: 31178258
[17]	Glassman CR, Tsutsumi N, Saxton RA, et al. Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation[J]. Science, 2022, 376(6589):163-169. doi: 10.1126/science.abn8933 pmid: 35271300
[18]	Gilardi D, Gabbiadini R, Allocca M, et al. PK, PD, and interactions: The new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(9):797-806.
[19]	Wang J, Zhao X, Wan YY. Intricacies of TGF-β signaling in Treg and Th17 cell biology[J]. Cell Mol Immunol, 2023, 20(9):1002-1022. doi: 10.1038/s41423-023-01036-7 pmid: 37217798
[20]	Caiazzo G, Caiazzo A, Napolitano M, et al. The use of JAK/STAT inhibitors in chronic inflammatory disorders[J]. J Clin Med, 2023, 12(8):2865.
[21]	Qin Z, Wang R, Hou P, et al. TCR signaling induces STAT3 phosphorylation to promote TH17 cell differentiation[J]. J Exp Med, 2024, 221(3):e20230683.
[22]	Wang X, Han C, Yang D, et al. STAT3 and SOX-5 induce BRG1-mediated chromatin remodeling of RORCE2 in Th17 cells[J]. Commun Biol, 2024, 7(1):10. doi: 10.1038/s42003-023-05735-9 pmid: 38172644
[23]	Hindmarch DC, Malashanka S, Shows DM, et al. Janus kinase inhibitors differentially inhibit specific cytokine signals in the mesenteric lymph node cells of inflammatory bowel disease patients[J]. J Crohns Colitis, 2024, 18(4):628-637.
[24]	Salas A, Hernandez-Rocha C, Duijvestein M, et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(6):323-337. doi: 10.1038/s41575-020-0273-0 pmid: 32203403
[25]	van Gennep S, Fung I, Jong DC, et al. Histological outcomes and JAK-STAT signalling in ulcerative colitis patients treated with Tofacitinib[J]. J Crohns Colitis, 2024, 18(8):1283-1291.
[26]	Quiniou G, Andromaque L, Duclaux-Loras R, et al. Impaired reprogramming of the autophagy flux in maturing dendritic cells from crohn disease patients with core autophagy gene-related polymorphisms[J]. Autophagy, 2024, 20(8):1837-1853.
[27]	Neurath MF. Strategies for targeting cytokines in inflammatory bowel disease[J]. Nat Rev Immunol, 2024, 24(8):559-576. doi: 10.1038/s41577-024-01008-6 pmid: 38486124
[28]	Lovato P, Brender C, Agnholt J, et al. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease[J]. J Biol Chem, 2003, 278(19):16777-16781. doi: 10.1074/jbc.M207999200 pmid: 12615922
[29]	Villanueva A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15):1450-1462.
[30]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[31]	Park H, Lee S, Lee J, et al. Exploring the JAK/STAT signaling pathway in hepatocellular carcinoma: Unraveling signaling complexity and therapeutic implications[J]. Int J Mol Sci, 2023, 24(18): 13764.
[32]	Xiao Y, Li Y, Shi D, et al. MEX3C-mediated decay of SOCS3 mRNA promotes JAK2/STAT3 signaling to facilitate metastasis in hepatocellular carcinoma[J]. Cancer Res, 2022, 82(22):4191-4205. doi: 10.1158/0008-5472.CAN-22-1203 pmid: 36112698
[33]	Lin L, Chen Q. Yadanziolide A inhibits proliferation and induces apoptosis of hepatocellular carcinoma via JAK-STAT pathway: A Preclinical Study[J]. Biology (Basel), 2024, 13(7): 528.
[34]	Hashemi M, Sabouni E, Rahmanian P, et al. Deciphering STAT3 signaling potential in hepatocellular carcinoma: Tumorigenesis, treatment resistance, and pharmacological significance[J]. Cell Mol Biol Lett, 2023, 28(1):33. doi: 10.1186/s11658-023-00438-9 pmid: 37085753
[35]	Zhou Q, Tian W, Jiang Z, et al. A positive feedback loop of AKR1C3-mediated activation of NF-κB and STAT3 facilitates proliferation and metastasis in hepatocellular carcinoma[J]. Cancer Res, 2021, 81(5):1361-1374. doi: 10.1158/0008-5472.CAN-20-2480 pmid: 33361392
[36]	Li Y, Song Z, Han Q, et al. Targeted inhibition of STAT3 induces immunogenic cell death of hepatocellular carcinoma cells via glycolysis[J]. Mol Oncol, 2022, 16(15):2861-2880. doi: 10.1002/1878-0261.13263 pmid: 35665592
[37]	Ni Y, Low JT, Silke J, et al. Digesting the role of JAK-STAT and cytokine signaling in oral and gastric cancers[J]. Front Immunol, 2022, 13:835997.
[38]	Yang YL, Liu P, Li D, et al. Stat-3 signaling promotes cell proliferation and metastasis of gastric cancer through PDCD4 downregulation[J]. Kaohsiung J Med Sci, 2020, 36(4):244-249.
[39]	Huo C, Gu Y, Wang D, et al. STAT1 suppresses the transcriptional activity of TRIM21 in gastric cancer[J]. J Cancer Res Clin Oncol, 2023, 149(17):15335-15348. doi: 10.1007/s00432-023-05307-8 pmid: 37639009
[40]	Suresh RN, Jung YY, Mohan CD, et al. A new triazolyl-indolo-quinoxaline induces apoptosis in gastric cancer cells by abrogating the STAT3/5 pathway through upregulation of PTPεC[J]. Drug Dev Res, 2023, 84(8):1724-1738.
[41]	Zhou J, Li T, Chen H, et al. ADAMTS10 inhibits aggressiveness via JAK/STAT/c-MYC pathway and reprograms macrophage to create an anti-malignant microenvironment in gastric cancer[J]. Gastric Cancer, 2022, 25(6):1002-1016. doi: 10.1007/s10120-022-01319-4 pmid: 35925524
[42]	Ghasemian A, Omear HA, Mansoori Y, et al. Long non-coding RNAs and JAK/STAT signaling pathway regulation in colorectal cancer development[J]. Front Genet, 2023, 14:1297093.
[43]	Heichler C, Scheibe K, Schmied A, et al. STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis[J]. Gut, 2020, 69(7):1269-1282. doi: 10.1136/gutjnl-2019-319200 pmid: 31685519
[44]	Liu J, Xing R, Shao J, et al. Relationship between MUC4 variants and metastatic recurrence in colorectal cancer[J]. Int J Gen Med, 2023, 16:5077-5087. doi: 10.2147/IJGM.S437957 pmid: 37942474
[45]	You AB, Yang H, Lai CP, et al. CMTR1 promotes colorectal cancer cell growth and immune evasion by transcriptionally regulating STAT3[J]. Cell Death Dis, 2023, 14(4):245. doi: 10.1038/s41419-023-05767-3 pmid: 37024465
[46]	Wei XH, Liu YY. Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy[J]. Front Pharmacol, 2023, 14:1326281.
[47]	Taylor PC, Choy E, Baraliakos X, et al. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases[J]. Rheumatology (Oxford), 2024, 63(2):298-308.
[48]	Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis[J]. N Engl J Med, 2012, 367(7):616-624.
[49]	Sandborn WJ, D'Haens GR, Sands BE, et al. Tofacitinib for the treatment of ulcerative colitis: An integrated summary of up to 7.8 years of safety data from the global clinical programme[J]. J Crohns Colitis, 2023, 17(3):338-351.
[50]	Garrido I, Lopes S, Macedo G. Hit the road JAK! The role of new oral treatment in inflammatory bowel disease[J]. Inflamm Bowel Dis, 2021, 27(12):2010-2022. doi: 10.1093/ibd/izab037 pmid: 33742651
[51]	Shawky AM, Almalki FA, Abdalla AN, et al. A comprehensive overview of globally approved JAK inhibitors[J]. Pharmaceutics, 2022, 14(5): 1001.
[52]	Loftus EJ, Panés J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn's disease[J]. N Engl J Med, 2023, 388(21):1966-1980.
[53]	Guo J, Wang LY, Wu J, et al. The JAK2 inhibitor AG490 regulates the Treg/Th17 balance and alleviates DSS-induced intestinal damage in IBD rat[J]. Clin Exp Pharmacol Physiol, 2020, 47(8):1374-1381.
[54]	Wang D, Yin J, Dong R, et al. Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats[J]. Dig Liver Dis, 2015, 47(4):315-323.
[55]	Lin Z, Liu Y, Xu T, et al. STAT3-mediated promoter-enhancer interaction up-regulates inhibitor of DNA binding 1 (ID1) to promote colon cancer progression[J]. Int J Mol Sci, 2023, 24(12): 10041.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 55

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Su Rui, Wang Cunkai, Wang Dingxin, Cai Conghui, Zhang Jian, Hou Hongtao, Bai Yun. Efficacy and safety of anticoagulant therapy in patients with cirrhosis: A meta-analysis [J]. Clinical Focus, 2025, 40(4): 293-303.
[2]	Qi Xueting, Li Guona, Xue Rong, Zhang Junfang, Jia Jingjing, Huang Wenhui, Li Yingping. Characteristics of single-center peritoneal dialysis-associated peritonitis [J]. Clinical Focus, 2025, 40(4): 334-338.
[3]	. [J]. Clinical Focus, 2025, 40(4): 377-380.
[4]	Lin Tao, Du Taoming, Li Ya, Feng Yuling, Song Huizhen, Yu Qin. Value of T₂WI signal intensity and gadobemeglumine enhanced MRI hepatobiliary phase parameters in evaluating liver function of cirrhosis patients [J]. Clinical Focus, 2025, 40(3): 251-256.
[5]	Tong Mingxia, Chen Ke, Xiang Xiaocong, Zhou Lifeng. Analysis of lean metabolic-associated fatty liver disease among young and middle-aged people and its risk factors [J]. Clinical Focus, 2025, 40(2): 128-132.
[6]	Qian Chenying, Yan Wenjun, Huang Yan, Zhao Zhi. Analysis of risk factors for multidrug-resistant bacterial infection in patients with decompensated cirrhosis [J]. Clinical Focus, 2025, 40(2): 143-146.
[7]	Sun Ya, Yang Shuang. Value of ultrasound-guided attenuation parameter in the quantitative assessment of hepatic steatosis [J]. Clinical Focus, 2025, 40(2): 158-161.
[8]	Gou Caixia, Zhang Jie, Baoyixiamu·Ababaikeli , Wang Yiming, Yao Lei, Zheng Rongjiong, Pan Jinliang, Lu Xiaobo. Analysis of influencing factors of sleep quality and metabolically associated fatty liver disease in the physical examination population [J]. Clinical Focus, 2025, 40(1): 33-38.
[9]	Hu Rongqiu, Yan Le. Causal relationship between reflux esophagitis and otitis media: a two-sample Mendelian randomization analysis in the European population [J]. Clinical Focus, 2024, 39(12): 1089-1094.
[10]	Zhang Shasha, Zhao Yingchun, Zhou Hongxia. Effect of low-level viremia on the incidence of hepatocellular carcinomas in patients with hepatitis B cirrhosis treated with entecavir [J]. Clinical Focus, 2024, 39(11): 980-983.
[11]	. [J]. Clinical Focus, 2024, 39(11): 1035-1039.
[12]	. [J]. Clinical Focus, 2024, 39(10): 935-939.
[13]	Qin Qiaoling, Mo Ranghui, Chen Xinyi. Efficacy and safety of the direct-acting anti-HCV therapy based on efavirenz-containing regimen on HIV/HCV co-infected patients [J]. Clinical Focus, 2024, 39(10): 921-924.
[14]	Li Zhenan, Zhu Xuejuan, Li Shang, Wang Junmin. Effect of glucocorticoids with varied courses on the prevention of esophageal stricture after esophageal submucosal dissection [J]. Clinical Focus, 2024, 39(10): 896-900.
[15]	Gu Dandan, Zhou Xiaoxian, Wang Jingxian, Wu Chunxiao. Rectal cap polyposis: A case report and literature review [J]. Clinical Focus, 2024, 39(9): 828-832.